Dermira, Inc. (DERM): Price and Financial Metrics
GET POWR RATINGS... FREE!
DERM Stock Price Chart Interactive Chart >
DERM Price/Volume Stats
|Current price||$3.95||52-week high||$10.20|
|Prev. close||$4.30||52-week low||$3.04|
|Day high||$4.49||Avg. volume||55,009|
|50-day MA||$4.31||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||68.40M|
Dermira, Inc. (DERM) Company Bio
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The company was founded in 2010 and is based in Menlo Park, California.
Most Popular Stories View All
DERM Latest News Stream
|Loading, please wait...|
DERM Latest Social Stream
View Full DERM Social Stream
Latest DERM News From Around the Web
Below are the latest news stories about Journey Medical Corp that investors may wish to consider to help them evaluate DERM as an investment opportunity.
Journey Medical Corporation (NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therapeutics Inc (NASDAQ: VYNE) The transaction includes cash payments of million and potential milestones of up to 0 million. Approved by the FDA nearly 50 years ago, minocycline is a well-established molecule that has been prescribed, in oral formulation, over 30 million times in the past decade. Amze
Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline)
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition expands Journey Medical’s portfolio to nine marketed dermatology products East West Bank Credit agreement expanded to $30.0 million SCOTTSDALE, Ariz., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focus
Six Arizona companies went public this year, including ones in the health care, proptech and car wash industries. See how their shares performed since debuting on public markets.
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent
DERM Price Returns